Innovation Pharmaceuticals Inc (IPIX)

[Tails]

European trial for K will start at UofBologna soon - they were waiting for K to achieve higher dosage in the P1 trial.
The purchase of B last summer involved a change of the P testing. POC in Europe was cancelled.
B phase 2b became the priority with P going thru the US testing process. This effectively delayed P testing about 6-9 months, but will get P to approval in US quicker and saves CTIX $$.
This was a controversial move as evidenced by the share price gyrations since Sept 2013. I think it was a wise move on all fronts.

Check out the R&R presentation from 9/2013 where Leo explained the decision.

If B proves effective the move will be huge win for us.

IF K is efficacious then - Katy bar the door.

Go CTIX!